1)In the core US market (70~80% portion), the key is expanding coverage based on increasing the number of co-occurring diseases (indications)
This therapeutic model provides a promising, evidence-based solution to this growing epidemic by combining currently available and approved weight loss methods to optimize patient results and long-term outcomes
Scientists at University College London carried out the trial in 16 countries across Asia, Europe, North America, and South America
The decision to use Zepbound while breastfeeding should be made with a healthcare provider, weighing the benefits of breastfeeding against the need for the medication
Tirzepatide pricing has already softened through Lilly Directs cash-pay vials
Many women experience weight gain and fat accumulation in the waist region during their menopausal period [14]